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ABSTRACT
Background. Several clinical risk scores for patients with
colorectal liver metastases (CLM) were established in
cohorts of patients undergoing liver resection (LR) without
neoadjuvant chemotherapy (NAC). The purpose of the
study was to evaluate the predictive values of four common
risk scores in the setting of NAC and the impact of score
changes during NAC.
Methods. Risk scores (Fong, Nordlinger, Nagashima, and
Konopke) were retrospectively calculated for 336 patients
undergoing LR for CLM, including 109 patients without
and 227 patients with NAC. In patients with NAC, the
scores were calculated before and after NAC.
Results. In patients without NAC (n = 109), all risk
scores except the Konopke score showed a significant
correlation with disease-free survival (DFS). Only the
Nagashima score also was predictive for overall survival
(OS). In patients with NAC (n = 227), all scores except the
Konopke score were predictive for DFS and OS before and
after NAC. Score changes in the Fong and the Nagashima
score showed a significant correlation with DFS and OS.
Conclusions. Nagashima score was the most universally
applicable score and predicted prognosis in all tested scenarios.
Survival of patients with colorectal liver metastases
(CLM) largely depends on their chance to undergo poten-
tially curative surgical resection.
However, prognosis and outcome are determined by a
wide range of patient- and tumor-dependent variables,
including tumor size, lymph node positivity of the primary
tumor, synchronous metastases, and elevated carcinoem-
bryonic antigen amongst others1. To predict prognosis after
liver resection of CLM, several clinical risk scores have
been developed. The most commonly used scores are the
clinical risk score (CRS) by Fong, Nordlinger, Nagashima,
and Konopke2–5. All of these scores were established in
cohorts of patients undergoing liver resection without prior
chemotherapy.
Neoadjuvant chemotherapy (NAC) was introduced to
prolong progression-free survival in upfront resectable
metastases and to achieve secondary resectability in bor-
derline or nonresectable metastases6–8. NAC is now widely
used in clinical practice.
The increasing number of patients receiving NAC might
impede the general application of risk scores in the clinical
practice9. Furthermore, it remains unclear whether a
change in risk scores during NAC impacts on survival. To
clarify these issues, we analyzed a series of 336 patients
undergoing liver resection (LR) for CLM consisting of 227
patients who received NAC and of 109 patients who did
not.
MATERIALS AND METHODS
This is a retrospective analysis of 336 patients who
underwent liver resection for CLM at our institution from
May 2000 to December 2010. Data were extracted from a
prospective patient database, laboratory records, and
patients charts. The study was approved by the local ethics
committee at the Medical University Vienna, Austria.
Relevant data for this study included: demographic data,
number and size of metastases, primary tumor and lymph
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node stage, interval from diagnosis of primary tumor to
detection of metastases, carcinoembryonic antigen (CEA)
levels, resectability of any extrahepatic disease, type of
NAC, as well as overall (OS) and disease-free survival
(DFS).
Patients were divided into two groups depending on
whether they received NAC or not. Easily resectable, small
liver metastases with a good prognosis or patient’s wish
formed the basis of the decision of omitting NAC. Standard
duration of NAC was 3 months in patients with primarily
resectable metastases or until resectability in patients with
initially unresectable CLM. Resectable CLM are defined as
liver metastases, in which upfront R0 resection of all
hepatic lesions is possible, more than 30 % estimated
residual liver after resection and disease not in contact with
major vessels of the remnant liver. Clinical scores were
calculated before and after NAC, and change was classified
as decreasing, steady, or increasing scores.
Prognostic Scores
The following scores were calculated and compared: the
CRSs by Fong, Nordlinger, Nagashima, and Konopke2–5.
The detailed description of each CRS is shown in Table 1.
Based on the original publication of Fong et al., we used
the original stratification of two risk groups. All other
scores defined three risk groups2.
In patients without NAC, scores were calculated before
surgery. In patients with NAC, scores were calculated
before the start of NAC and immediately before liver
resection.
Scores were only calculated when all relevant parame-
ters were available. Patients with missing data were
excluded for the respective score calculation. Patients with
NAC were only included in statistical analysis of survival
curves if the clinical risk scores were available for both
time points of evaluation. Furthermore, the differences
between the scores before and after the administration of
NAC were calculated to show if hypothesized prognostic
improvement or decline would cause changes in survival
curves. Any reduction of the score number was classified as
-1, no change as 0, and any increase as ?1.
Statistical Analysis
Statistical analysis was performed using SPSS for
Windows, Version 20.0 (SSPS Inc., Chicago, IL). Metric
variables were expressed as mean or median ± standard
deviation. The comparison of variables before and after
NAC was performed by the paired t test if the differences
between the values before and after NAC were normally
distributed. If not, the Wilcoxon signed-rank test was used.
Survival curves were computed with a Kaplan–Meier graph
and compared with the log-rank test. In case of risk scores
with three risk groups, the log-rank test was combined
TABLE 1 Clinical risk scores
CRS criteria (1point for 1 risk factor) Risk groups
Fong 1. Largest liver metastasis[5 cm
2. Disease free interval\12 months
3. Number of liver metastases[1




Nordlinger 1. Age[60 a
2. Serosal invasion of primary tumor (CpT3)
3. Lymph node positive primary tumor (pN1)
4. Disease free interval\24 months
5. Number of liver metastases[3




Nagashima 1. Serosal invasion of primary tumor (CpT3)
2. Lymph node positive primary tumor (pN1)
3. Number of liver metastases C2
4. Largest liver metastasis C5 cm




Konopke 1. Number of liver metastases C4
2. CEA C200 ng/ml
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subsequently with a linear trend test. For comparison of
survival curves of patients with a score difference between
before and after NAC of -1, 0, or ?1, the Kaplan–Meier
method was combined with a linear trend test. A p value
\0.05 was considered to indicate statistical significance.
RESULTS
A total of 336 patients undergoing liver resection for
CLM were included in the study including patients without
(n = 109) and with NAC (n = 227). Patient characteristics
are shown in Table 2. The median age of the study popu-
lation was 63.0 (range, 28–87) years, and the median
follow-up was 42.0 (range, 0–140) months. Between
patients with and without NAC, no statistically significant
difference but a trend towards longer survival in patients
without NAC became apparent. Patients without NAC had
a longer DFS (14 vs. 9 months, p = 0.206) and OS (54 vs.
50 months, p = 0.584) than patients receiving NAC.
Patients with NAC had a significantly higher median
number of metastases (3 vs. 1, p =\ 0.0001), higher
median CEA levels (12.9 vs. 6.8 ng/ml, p = 0.023), and
suffered more often from synchronous liver metastatic
disease (60.7 vs. 40.4 %, p = 0.0007). A statistically not
significant higher number of pN1 primary tumors (65.6 vs.
56 %; p = 0.093) and larger diameters of metastases (4.6
vs. 3.5; p = 0.116) could be observed in patients with
NAC.
The majority of patients with NAC (81.1 %, n = 184)
had initially resectable CLM, whereas 18.9 % (n = 43)
had initially unresectable disease.
Those with initially resectable disease received in
48.4 % (n = 89) NAC based on Oxaliplatin, in 10.9 %
(n = 20) based on Irinotecan, in 36.4 % (n = 67) a com-
bination with Avastin, and in 4.3 % (n = 8) combination
with Cetuximab. Patients with initially unresectable disease
received in 30.2 % (n = 13) NAC based on Oxaliplatin, in
7.0 % (n = 3) based on Irinotecan, in 41.9 % (n = 18) a
combination with Avastin, and in 20.9 % (n = 9) a com-
bination with Cetuximab.
Tumor-specific variables altered in patients with NAC
compared with baseline values. There was a significant
decrease in the median diameter of metastases
(3.5 ± 3.3 cm vs. 2.0 ± 2.9 cm, p\ 0.001) and in CEA
TABLE 2 Characteristics of all patients
All patients (n = 336) Patients without NAC (n = 109) Patients with NAC (n = 227)
Value %/Range Value %/Range Value %/Range
Male 214 64 76 70 138 61
Female 122 36 33 30 89 39
Median age (years) 63 28–87 66 41–87 62 28–83
Primum
Colon 221 66 73 67 148 65
Rectal 111 33 32 30 79 35
T1 9 3 2 2 7 3
T2 45 13 18 17 27 12
T3 240 71 73 67 167 74
T4 28 8 11 10 17 8
Lymph node positive primary 202 60 58 53 144 63
Median CEA (ng/ml) 11.1 0–4858 6.8 0.7–3800 12.9 0–4858
Median number of metastases 2.0 1–12 1.0 1–10 3.0 1–12
Mean diameter of the largest metastasis (cm) 3.9 0.1–23 3.5 0.1–12 4.6 0.1–23
Synchronous 182 54 44 40 138 61
Metachronous 154 46 65 60 89 39
Median DFI (months, 154 patients) 15 0–180 16 1–180 15 0–81
\12 months 229 68 64 59 165 73
\24 months 284 86 86 79 198 87
Resectable extrahepatic metastases 39 12 15 14 24 11
Median OS (months) 51 95% CI 42–60 54 95% CI 38–70 50 95% CI 38–62
Median DFS (months) 10 95% CI 8–12 14 95% CI 7–21 9 95% CI 7–11
NAC neoadjuvant chemotherapy, CEA carcinembryonic antigen, DFI disease free interval, time between resection of primary cancer and
diagnosis of liver metastases, OS overall survival, DFS disease-free survival, CI confidence interval
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levels (12.7 ± 458.0 vs. 6.6 ± 508.9 ng/ml; p\ 0.001)
after NAC, whereas the median number of metastases
remained virtually unchanged (3.0 ± 2.1 vs. 2.0 ± 2.7;
p = 0.462). During NAC, the diameter of the largest
metastases decreased in 71.7 % (n = 162), remained the
same in 8.4 % (n = 19), and increased in 19.9 %
(n = 45). The CEA level decreased in 58.3 % (n = 127),
remained the same in 8.7 % (n = 19), and increased in
33.0 % (n = 72).
Radiological imaging before initiation of NAC showed
resectable extrahepatic metastases in 24 patients (10.6 %),
whereas intraoperatively resectable extrahepatic metas-
tases were found in 27 patients (11.9 %).
Predictive Value of Clinical Scores in Patients
without NAC
In patients without NAC, the Fong, Nordlinger, Naga-
shima, and Konopke scores could be calculated for 106,
103, 103, and 109 patients, respectively. Correlations of
the CRSs with DFS and OS for patients without NAC are
shown in Table 3. Regarding the prediction of DFS, Fong,
Nordlinger, and Nagashima scores were able to show
significant differences between the risk groups. However,
only the Nagashima score was of predictive value for OS
in patients without NAC.
Predictive Value of Clinical Scores in Patients
with NAC
The Fong, Nordlinger, Nagashima, and Konopke scores
could be calculated for 212, 218, 218, and 217 patients,
respectively. Correlations of the CRSs with DFS and OS in
patients with NAC are shown in Table 3.
Before and after NAC, all risk scores showed significant
differences in DFS between the risk groups. Before NAC,
Fong, Nordlinger, and Nagashima scores were of predic-
tive value for OS. After NAC, all four CRSs showed
significant differences in OS between the risk groups.
Clinical Score Change During NAC
Overall, score increases during NAC were associated
with a worsening in clinical outcome. The scores
decreased, and therefore improved, in 27.4 % (n = 58,
Fong) versus 23.9 % (n = 52, Nordlinger) versus 26.1 %
(n = 57, Nagashima) versus 15.7 % (n = 34, Konopke).
They remained the same in 63.2 % (n = 134, Fong) versus
67.0 % (n = 146, Nordlinger) versus 62.8 % (n = 137,
Nagashima) versus 76.0 % (n = 165, Konopke). They
increased in 9.4 % (n = 20, Fong) versus 9.2 % (n = 20,
Nordlinger) versus 11.0 % (n = 24, Nagashima) versus
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Whereas there was only a trend towards reduced sur-
vival in patients with increasing Nordlinger and Konopke
scores, decreasing, steady, or increasing Fong and Naga-
shima scores had significant impact on DFS and OS
(Table 4). Kaplan–Meier curves for patients with score
changes of the Fong and Nagashima scores during NAC are
shown in Figs. 1a–d.
DISCUSSION
Several clinical risk scores are used currently in clinical
practice to predict prognosis after resection of CLM. Many
of these were developed more than a decade ago when
NAC was rarely applied in patients with CLM. Today, the
consensus guidelines of the European Society for Medical
Oncology recommend NAC as current standard in the
management of potentially resectable liver metastases10. In
patients with good prognosis and a single, small (\2 cm)
liver metastases upfront surgery may be considered10.
The clinical practice guidelines of the National Com-
prehensive Cancer Network stated that in case of
resectable synchronous liver and/or lung metastases only,
upfront surgery as well as NAC followed by synchronous
or staged colectomy and resection of the metastatic disease
is recommended11. However, even though the number of
patients receiving NAC is increasing, data on the predictive
value of CRS in these patients are scarce.
We retrospectively assessed the predictive values of the
Fong, Nordlinger, Nagashima, and Konopke scores in
patients with and without NAC. The selection of the scores
was based on the widespread clinical use of these scoring
systems, the easily accessible data required for the calcu-
lation of these four scores, and the possibility to compare
our findings with a previous study, published by Ayez et al.
That study assessed the predictive value of these scores
before and after NAC and concluded that the scores are not
reliable when used to predict survival before the start of
neoadjuvant treatment but are useful when calculated
thereafter.
In patients with NAC, they found that only the Naga-
shima score regarding DFS and only the Nordlinger score
regarding OS predicted outcome before and after NAC
reliably9. A similar study reported that the Fong and the
Nordlinger score could not predict OS in the setting of
NAC12.
Regarding the reliability of risk scores in patients
without NAC, controversial results were published in the
recent literature9,13. Some studies demonstrated the use-
fulness of the Fong and Nordlinger scores to determine
significant differences in DFS and OS9,13,16,17. However,
another study contradicted these results15. Assessments of
the Nagashima and Konopke scores regarding their accu-
racy to predict DFS and OS are rare, but some authors
concluded that they seem to be useful tools9,13.
In the study population of Ayez et al., 193 patients
received upfront surgery and 159 underwent NAC9. In
comparison, we could include more patients with NAC but
fewer patients without NAC. This might explain why we
could observe more significant differences between risk
groups in patients with NAC but also might have missed a
significant difference in patients without NAC due to a lack
of power.
Ayez et al. described a DFS of 9 months [95 % confi-
dence interval (CI) 7–11] and an OS of 47 months (95 %
CI 33–61) in patients with NAC. In our study population,
similar median DFS (9 months, 95 % CI 7–11) and OS
(50 months, 95 % CI 38–62) were observed.
TABLE 4 DFS and OS in patients with decreasing, steady or increasing scores during NAC
C-1 0 ?1
DFS median DFS DFS DFS p value
D Fong (n = 212) 11.0 (58) 10.0 (134) 6.0 (20) 0.014
D Nordlinger (n = 218) 9.0 (52) 10.0 (146) 5.0 (20) 0.131
D Nagashima (n = 218) 14.0 (57) 9.0 (137) 6.0 (24) 0.012
D Konopke (n = 217) 6.0 (34) 10.0 (165) 4.0 (18) 0.502
OS median OS OS OS p value
D Fong (n = 212) 81.0 (58) 61.0 (134) 28.0 (20) 0.004
D Nordlinger (n = 218) 72.0 (52) 51.0 (146) 30.0 (20) 0.109
D Nagashima (n = 218) 65.0 (57) 61.0 (137) 33.0 (24) 0.032
D Konopke (n = 217) 61.0 (34) 49.0 (165) 28.0 (18) 0.194
Bold values are statistically significant
DFS disease-free survival, OS overall survival, () n
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In patients without NAC, Ayez et al. reported a median
DFS of 14 months (95 % CI 11–17) and OS of 43 months
(95 % CI 34–52). Our patients without NAC reached a
similar median DFS (14 months, 95 % CI 7–21), whereas
regarding OS, they performed markedly better (54 months,
95 % CI 38–70). As a reason, we assume that patients with
good tumor biology and good prognosis more often
underwent upfront surgery in our study population.
This selection bias in favor of upfront surgery for
patients with favorable tumor biology and good prognostic
clinical parameters might be a potential limitation of our
study. We observed that patients who received NAC had a
significantly higher median number and larger diameters of
metastases, higher median CEA levels, and suffered more
often from synchronous liver metastases and pN1 primary
tumors. All of these parameters indicate a more aggressive
metastatic disease. It is possible that scores of patients who
received upfront surgery due to their good tumor biology
are no longer predictive or at least of less predictive value.
A further limitation might be the inherent problem in
retrospective analyses that must be taken into account
when interpreting the results. However, the large sample
size and the long follow-up might outweigh these limita-
tions, particularly regarding the issues that the study was
focused on.
Due to consistent accuracy of the Nagashima score
through all our patient’s cohorts, it might be the most
predictive. In contrast to the Konopke score, which was
FIG. 1 Kaplan–Meier curves of patients with increasing, steady or decreasing Fong and Nagashima scores
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rather poorly performing across all our patients, the
Nagashima score includes more variables. This probably
allows for better patient characterization. Furthermore,
patients are distinguished in three risk groups, which is
probably more accurate than only two risk groups (Fong
score). Indeed, the Nordlinger and the Nagashima score
included similar variables and showed similar efficacy
regarding overall outcome in our study. However, analyz-
ing score changes during NAC, the Nagashima score was
more predictive probably because this score included more
changeable parameters than the Nordlinger score.
The assessment of the impact of score changes during
NAC showed that only changes of Fong and Nagashima
scores were associated with significant differences in
survival. A reason for the poorer performance of the
other scores might be that none of these CRSs exclu-
sively used changeable parameters for calculation. For
example, although the Nordlinger score considers six
parameters, only two of them can be influenced by NAC.
The Fong score changed in 36.8 %, the Nordlinger in
33.1 %, the Nagashima in 37.1 %, and the Konopke
score in 24.0 %. Obviously, the Nordlinger and the
Konopke are slightly more resistant to the influence of
NAC. Additionally, even if parameters change during
chemotherapy, this does not mean that they reach the
cutoff values leading to score changes. Thus, to improve
the impact of clinical scores during NAC on prediction
of DFS and OS the use of continuous parameters should
be considered.
In our institution, the use of CRSs did not influence the
surgical management of CLMs. The process of selecting
tailored therapy for each patient is still a goal of interdis-
ciplinary conferences, including surgeons, oncologists, and
radiologists. We believe that LR also should be offered to
patients with high CRS; however, these patients might
benefit from shorter follow-up intervals or an intensified
NAC. Thus, further studies are needed to determine the
outcome of high-risk patients and liver resection after NAC.
To conclude, only the Nagashima score was able to
predict DFS and OS in all patient groups, irrespective of
whether calculated before or after NAC. Calculation of
changes of the Fong or the Nagashima score can be a
valuable tool to estimate the clinical outcome of patients
undergoing neoadjuvant treatment.
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